rosacea
Conditions
Interventions
Carvedilol: oral carvedilol 5 mg twice per day
Gabapentin:oral gabapentin 300 mg thrice per day
Sponsors
Dermatology Department, Southwest Hospital, Third Military Medical University, Chongqing, China
Eligibility
Sex/Gender
All
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: (1). Patients aged fron 18 to 40 years old (including 18 years old and 40 years old, regardless of gender) (2). In line with the diagnostic criteria of ETR, the main manifestations are recurrent flushing and persistent erythema of the facial skin. (3). A variety of inducing factors aggravated the clinical symptoms of patients, including temperature change, sun exposure, spicy stimulating food, topical drugs, mental factors and so on. (4). Ability to follow study or follow-up procedures and collaborate to observe adverse events and outcomes (5). Written informed consent signed by the patient or his/her guardian.
Exclusion criteria
Exclusion criteria: (1) Patients who were allergic to carvedilol or gabapentin. (2) Patients with bronchial asthma or hypotension and bradycardia. (3) Participated in the clinical study of any investigational drug within 1 month before enrollment. (4) Medications that affect rosacea symptoms, such as retinoids, are being used. (5) Patients with serious heart, liver, lung, kidney and other organ diseases and hematopoietic system diseases that researchers consider unsuitable for clinical trials. (6) Patients with malignant tumors or immunosuppression. (7) patients with acne, atopic dermatitis, hormone-dependent dermatitis and other facial skin diseases. (8) patient has a history of sun exposuren in the past month. (9) patients with drug, tobacco and alcohol addiction. (10) Pregnant or lactating women and those planning to pregnant within one year. (11) Inability or unwillingness to cooperate due to mental or neurological disorders. (12) Patients with bradycardia. (13) Patients with hypotension. (14) Patients with papulopustular rosacea (PPR), phymatous rosacea (PHY), and ocular rosacea (OR).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| clinician’s Erythema Assessment (CEA); | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient Self-Assessment (PSA);flushing severity scale (GFSS);Pittsburgh Sleep Quality Index (PSQI);Visual Analogue Scale for migraine (VAS);Generalized Anxiety Disorder-7 (GAD-7) ;Patient Health Questionnaire-9 (PHD-9); | — |
Countries
China
Contacts
Public ContactJian Li
Dermatology Department, Southwest Hospital, Third Military Medical University, Chongqing, China
Outcome results
None listed